AI Prescription Refill Debate in Utah Sparks Questions

A prescription refill initiative in Utah has ignited a significant discussion in the medical community about the role of artificial intelligence (AI) in healthcare. The program, which started quietly earlier this year, is centered around an AI chatbot known as Doctronic. This tool enables Utah residents to bypass the usual doctor’s visit to refill prescriptions online.

While this approach offers a convenience factor, it raises important questions and concerns among medical professionals and legal experts. A central point of contention is whether AI can take on tasks traditionally reserved for licensed medical practitioners. State laws currently limit prescription authority only to licensed professionals, but proponents argue these regulations should evolve alongside technological advancements.

Dr. Eric Bressman of the University of Pennsylvania highlighted the threshold that’s been crossed by equipping AI with a near-medical license. Despite existing laws that prohibit AI’s practice of medicine, Bressman and others are not against AI’s role, provided it meets stringent standards comparable to human doctors.

The program operates under a “regulatory sandbox” that allows certain legal waivers for promising AI technologies. A board of AI specialists, although not consisting of doctors, oversees the program ensuring multiple safeguards. Human oversight is still present, with doctors reviewing all initial refill orders.

Dr. Alan Smith, head of Utah’s medical licensing board, expressed concerns over the risks involved in automatic medication renewals. These concerns include drug side effects and interactions, which might necessitate physician intervention.

Medical regulation is generally a federal responsibility, but states license medical professionals. This brings a complex layer to the AI’s role in prescribing medicine. The Food and Drug Administration (FDA) oversees AI affecting medical decisions, a point some experts argue has been crossed by Doctronic.

Other states like Texas and Wyoming are paving the way for AI-driven healthcare solutions. Legislation in states such as Iowa and Idaho is looking to formally recognize AI in medicine, following templates from organizations like the Cicero Institute.

Cicero’s director for health policy, Adam Meier, suggests that economic concerns from medical professionals contribute to hesitations about adopting AI. However, perceived patient safety risks remain a higher priority according to Dr. Smith, who warns about specific medications that pose health dangers when conditions change.

Zach Boyd, Utah’s AI office chief, indicates that Doctronic has been cautious, often referring straightforward cases to doctors. To address safety fears, some medications have been removed from the AI refill list.

Doctronic plans to release peer-reviewed studies to validate its technology. Initial studies show that Doctronic aligns with human doctor diagnoses 80% of the time, yet experts believe more rigorous assessments should be required for prescription refills.

FDA’s current hands-off stance underlines the complexity of regulating AI. This approach recalls early 20th-century medical standards before they were standardized. The FDA has yet to authorize any AI chatbots, with an emphasis on safety while fostering innovation.

As Doctronic expands into states with varied regulations, questions about public trust and long-term implications arise. Companies may see short-term growth at the expense of potential backlash over public perception.

The Associated Press receives support to explore science and health content, with editorial independence assured.